Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Cannabinoids and Schizophrenia: Risks and Therapeutic Potential.

Manseau MW, Goff DC.

Neurotherapeutics. 2015 Oct;12(4):816-24. doi: 10.1007/s13311-015-0382-6.

PMID:
26311150
2.

Substance use in people at clinical high-risk for psychosis.

Russo DA, Stochl J, Painter M, Jones PB, Perez J.

BMC Psychiatry. 2014 Dec 24;14:361. doi: 10.1186/s12888-014-0361-1.

3.

Increasing endocannabinoid levels in the ventral pallidum restore aberrant dopamine neuron activity in the subchronic PCP rodent model of schizophrenia.

Aguilar DD, Chen L, Lodge DJ.

Int J Neuropsychopharmacol. 2014 Oct 31;18(1). pii: pyu035. doi: 10.1093/ijnp/pyu035.

4.

Prescribing smoked cannabis for chronic noncancer pain: preliminary recommendations.

Kahan M, Srivastava A, Spithoff S, Bromley L.

Can Fam Physician. 2014 Dec;60(12):1083-90. Review.

5.

Approach to cannabis use disorder in primary care: focus on youth and other high-risk users.

Turner SD, Spithoff S, Kahan M.

Can Fam Physician. 2014 Sep;60(9):801-8, e423-32. Review. English, French.

6.

Linkage analysis followed by association show NRG1 associated with cannabis dependence in African Americans.

Han S, Yang BZ, Kranzler HR, Oslin D, Anton R, Farrer LA, Gelernter J.

Biol Psychiatry. 2012 Oct 15;72(8):637-44. doi: 10.1016/j.biopsych.2012.02.038. Epub 2012 Apr 19.

7.

Do we have any solid evidence of clinical utility about the pathophysiology of schizophrenia?

Lawrie SM, Olabi B, Hall J, McIntosh AM.

World Psychiatry. 2011 Feb;10(1):19-31.

8.

Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization.

Foti DJ, Kotov R, Guey LT, Bromet EJ.

Am J Psychiatry. 2010 Aug;167(8):987-93. doi: 10.1176/appi.ajp.2010.09020189. Epub 2010 May 17.

9.

Immunoactive effects of cannabinoids: considerations for the therapeutic use of cannabinoid receptor agonists and antagonists.

Greineisen WE, Turner H.

Int Immunopharmacol. 2010 May;10(5):547-55. doi: 10.1016/j.intimp.2010.02.012. Epub 2010 Feb 25. Review.

10.

Cannabis-induced bipolar disorder with psychotic features: a case report.

Khan MA, Akella S.

Psychiatry (Edgmont). 2009 Dec;6(12):44-8.

11.

The analgesic potential of cannabinoids.

Elikkottil J, Gupta P, Gupta K.

J Opioid Manag. 2009 Nov-Dec;5(6):341-57. Review. Erratum in: J Opioid Manag. 2010 Jan-Feb;6(1):14. Elikottil, Jaseena [corrected to Elikkottil, Jaseena].

12.

Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances.

Ren Y, Whittard J, Higuera-Matas A, Morris CV, Hurd YL.

J Neurosci. 2009 Nov 25;29(47):14764-9. doi: 10.1523/JNEUROSCI.4291-09.2009.

Items per page

Supplemental Content

Write to the Help Desk